Global Health and the Future Role of the United States
Actions for a strong global health strategy

**Sustain Progress Toward Malaria Elimination**
Relevant agencies should continue their commitment to the fight against malaria through the President’s Malaria Initiative and collaborative work with all partners toward elimination of the disease.

Since its creation, the President’s Malaria Initiative has reduced malaria mortality by 48% in focus countries.

**Improve Survival in Women and Children**
Congress should increase funding for USAID to augment the agency’s investments in ending preventable maternal and child mortality, defined as global maternal mortality rates of fewer than 70 deaths per 100,000 live births by 2020 and fewer than 25 child deaths per 1,000 live births by 2030.

More than 6 million children and 300,000 mothers die each year due to largely preventable causes.

**Confront the Threat of Tuberculosis**
Relevant agencies should conduct a thorough global threat assessment of rising tuberculosis (TB) levels, including multi-drug-resistant TB and extensively drug-resistant TB. They should then execute a plan of action, including governance structure and priority activities, for developing and investing in new diagnostics, drugs, vaccines, and delivery systems.

Treating drug-resistant tuberculosis can be 100x more expensive than treating non-resistant tuberculosis.

**Combat Antimicrobial Resistance**
Relevant agencies should continue to invest in national capabilities and accelerate the development of international capabilities to detect, monitor, report, and combat antibiotic resistance.

The current rate of antimicrobial resistance is projected to result in a loss of 10 million lives per year and a cumulative loss of $100 trillion in global economic output by 2050. Combating resistance could mitigate these losses, maintain the integrity of treatment, and protect the progress achieved in reducing the burden of critical infectious diseases.

**Build Public Health Capacity in Low- and Middle-Income Countries**
Relevant agencies should expand training and information exchange efforts to increase the capacity of low- and middle-income countries to respond to both public health emergencies and acute mass casualty disasters.

The U.S. currently imports 75-80 percent of raw materials for drugs meant for the U.S. domestic market, which increases susceptibility to the effects of a public health emergency should an outbreak occur in an exporting country.

**Improve International Emergency Response Coordination**
The presidential administration should create a coordinating body for international public health emergency response that is accountable for international and domestic actions and oversees preparedness for and responses to global health security threats.

U.S. agencies had to wait for seven months for funding to respond to the Zika outbreak, threatening the safety of the American people and weakening other health capabilities.

**Envision the Next Generation of PEPFAR**
Congress should fund the President’s Emergency Plan for AIDS Relief (PEPFAR) at current levels, and allow for more flexibility within the PEPFAR program by continuing to relax specific funding targets for all program areas.

13 percent higher employment rates were found among men in PEPFAR countries than in non-PEPFAR countries.

**Combat Antimicrobial Resistance**
Relevant agencies should continue to invest in national capabilities and accelerate the development of international capabilities to detect, monitor, report, and combat antibiotic resistance.

The current rate of antimicrobial resistance is projected to result in a loss of 10 million lives per year and a cumulative loss of $100 trillion in global economic output by 2050. Combating resistance could mitigate these losses, maintain the integrity of treatment, and protect the progress achieved in reducing the burden of critical infectious diseases.

**Build Public Health Capacity in Low- and Middle-Income Countries**
Relevant agencies should expand training and information exchange efforts to increase the capacity of low- and middle-income countries to respond to both public health emergencies and acute mass casualty disasters.

The U.S. currently imports 75-80 percent of raw materials for drugs meant for the U.S. domestic market, which increases susceptibility to the effects of a public health emergency should an outbreak occur in an exporting country.

**Improve International Emergency Response Coordination**
The presidential administration should create a coordinating body for international public health emergency response that is accountable for international and domestic actions and oversees preparedness for and responses to global health security threats.

U.S. agencies had to wait for seven months for funding to respond to the Zika outbreak, threatening the safety of the American people and weakening other health capabilities.

**Confront the Threat of Tuberculosis**
Relevant agencies should conduct a thorough global threat assessment of rising tuberculosis (TB) levels, including multi-drug-resistant TB and extensively drug-resistant TB. They should then execute a plan of action, including governance structure and priority activities, for developing and investing in new diagnostics, drugs, vaccines, and delivery systems.

Treating drug-resistant tuberculosis can be 100x more expensive than treating non-resistant tuberculosis.

**Sustain Progress Toward Malaria Elimination**
Relevant agencies should continue their commitment to the fight against malaria through the President’s Malaria Initiative and collaborative work with all partners toward elimination of the disease.

Since its creation, the President’s Malaria Initiative has reduced malaria mortality by 48% in focus countries.
### Commit to Continued Global Health Leadership
Relevant agencies should invest in a targeted effort to reduce the costs and risks of developing, licensing, and introducing vaccines, therapeutics, diagnostics, and devices needed to address global health priorities. This can be accomplished by enabling innovative approaches for trial design, streamlining regulation, ensuring production capacity, creating market incentives, and building international capacity for research and development.

### Accelerate the Development of Medical Products
Relevant agencies should invest in a targeted effort to reduce the costs and risks of developing, licensing, and introducing vaccines, therapeutics, diagnostics, and devices needed to address global health priorities. This can be accomplished by enabling innovative approaches for trial design, streamlining regulation, ensuring production capacity, creating market incentives, and building international capacity for research and development.

<table>
<thead>
<tr>
<th>25 percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease is the leading cause of death globally and results in the highest health expenditure in most countries. Investing in cancer care and control could result in millions of avoidable deaths, achieving between $100 and 200 billion in global economic savings.</td>
</tr>
</tbody>
</table>

### Improve Digital Health Infrastructure
Relevant agencies of the U.S. government should convene an international group of public and private stakeholders to create a common digital health framework that addresses country-level needs ranging from integrated care to research and development.

### Transition Investments Toward Global Public Goods
Relevant agencies should systematically assess their approach to global health funding with an eye toward making long-term investments in high-impact, country-level programs.

<table>
<thead>
<tr>
<th>$50 billion</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. investments in the Global Polio Eradication Initiative are expected to generate returns of as much as $50 billion by 2035.</td>
</tr>
</tbody>
</table>

### Optimize Resources Through Smart Financing
Relevant agencies should expand efforts to complement direct bilateral support for health with financing mechanisms that include results-based financing; risk sharing; and attracting funding from private investment, recipient governments, and other donors.

<table>
<thead>
<tr>
<th>72 percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investing in health makes business sense. A mining company in Ghana implemented malaria controls that led to a 72% decrease in disease burden, saving the company roughly $600,000 per year.</td>
</tr>
</tbody>
</table>

### Promote Cardiovascular Health and Prevent Cancer
Relevant agencies, through their country offices, should provide seed funding to facilitate the mobilization and involvement of the private sector in addressing cardiovascular disease and cancer at the country level.

<table>
<thead>
<tr>
<th>15 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>The average time to develop a new drug and enter the market is 15 years and the average cost is $2.5 billion. Between 2000 and 2011, only 4% of new products were targeted at neglected diseases.</td>
</tr>
</tbody>
</table>

### Ensure Healthy and Productive Lives for Women and Children
Relevant agencies, their implementing partners, and other funders should support and incorporate proven, cost-effective interventions into their existing programs for ensuring that all children reach their developmental potential and become healthy, productive adults.

<table>
<thead>
<tr>
<th>25 percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early childhood interventions increase labor market participation, earnings, and economic growth, generating returns of up to 25 percent.</td>
</tr>
</tbody>
</table>

### Commit to Continued Global Health Leadership
The United States needs a global health workforce. Because of system limitations there is a standing vacancy rate of more than 30% for overseas positions within the Department of Health and Human Services.

<table>
<thead>
<tr>
<th>$100-$200 billion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investing in cancer care and control could result in millions of avoidable deaths, achieving between $100 and $200 billion in global economic savings.</td>
</tr>
</tbody>
</table>

### Promote Cardiovascular Health and Prevent Cancer
Relevant agencies, through their country offices, should provide seed funding to facilitate the mobilization and involvement of the private sector in addressing cardiovascular disease and cancer at the country level.

<table>
<thead>
<tr>
<th>15 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>The average time to develop a new drug and enter the market is 15 years and the average cost is $2.5 billion. Between 2000 and 2011, only 4% of new products were targeted at neglected diseases.</td>
</tr>
</tbody>
</table>

The National Academies of Sciences Engineering Medicine

nationalacademies.org/USglobalhealth